Skip to main content

Skin Diseases, Infectious

4
Pipeline Programs
10
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
3100%
+ 9 programs with unclassified modality

Competitive Landscape

10 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
amoxicillin/clavulanate potassium 1gmPhase 4
Sandoz
SandozAustria - Kundl
2 programs
2
DaptomycinPhase 31 trial
PTK 0796Phase 31 trial
Active Trials
NCT00430937Terminated194
NCT00865280Terminated143Est. Apr 2010
Bayer
BayerLEVERKUSEN, Germany
1 program
1
Tedizolid PhosphatePhase 31 trial
Active Trials
NCT01967225Completed125Est. Oct 2016
Ortho Development
2 programs
levofloxacinPHASE_2_3Small Molecule1 trial
LevofloxacinPHASE_3Small Molecule1 trial
Active Trials
NCT00257036Completed431Est. Feb 1993
NCT00257062Completed361Est. Apr 1994
Innovation Pharmaceuticals
1 program
sterile Phosphate Buffer SalineN/A1 trial
Active Trials
NCT05608382Completed50Est. Mar 2022
Johnson & Johnson
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
levofloxacinPHASE_2_3Small Molecule
Novartis
NovartisBASEL, Switzerland
1 program
PTK 0796PHASE_3
Paratek Pharmaceuticals
1 program
PTK 0796PHASE_3
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
Tedizolid PhophatePHASE_31 trial
Active Trials
NCT02276482Completed120Est. Sep 2018
Providence Therapeutics
1 program
CeftarolinePHASE_41 trial
Active Trials
NCT02582203Completed174Est. May 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Providence TherapeuticsCeftaroline
Merck & Co.Tedizolid Phophate
BayerTedizolid Phosphate
SandozPTK 0796
SandozDaptomycin
Ortho DevelopmentLevofloxacin
Ortho Developmentlevofloxacin
Innovation Pharmaceuticalssterile Phosphate Buffer Saline

Clinical Trials (8)

Total enrollment: 1,598 patients across 8 trials

NCT02582203Providence TherapeuticsCeftaroline

Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA

Start: Feb 2012Est. completion: May 2016174 patients
Phase 4Completed
NCT02276482Merck & Co.Tedizolid Phophate

Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)

Start: Mar 2015Est. completion: Sep 2018120 patients
Phase 3Completed
NCT01967225BayerTedizolid Phosphate

Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections

Start: Nov 2013Est. completion: Oct 2016125 patients
Phase 3Completed
NCT00865280SandozPTK 0796

Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

Start: Apr 2009Est. completion: Apr 2010143 patients
Phase 3Terminated
NCT00430937SandozDaptomycin

Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections

Start: Apr 2006194 patients
Phase 3Terminated
NCT00257062Ortho DevelopmentLevofloxacin

A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Uncomplicated Infections of the Skin and the Supportive Layers Beneath the Skin

Start: Jan 1993Est. completion: Apr 1994361 patients
Phase 3Completed
NCT00257036Ortho Developmentlevofloxacin

A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Mild to Moderate Infections of the Skin and the Supportive Layers Beneath the Skin

Start: Jul 1991Est. completion: Feb 1993431 patients
Phase 2/3Completed
NCT05608382Innovation Pharmaceuticalssterile Phosphate Buffer Saline

Effect of an Antiseptic Solution on the Skin Microbiome

Start: Mar 2022Est. completion: Mar 202250 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.